Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer

NCT03912818 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT03912818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03912818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Terminated
Start date
April 10, 2019
Completion date
August 11, 2022
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder adenocarcinoma, bladder mixed adenocarcinoma, bladder squamous cell carcinoma, bladder urothelial carcinoma, infiltrating bladder urothelial carcinoma sarcomatoid variant, infiltrating bladder urothelial carcinoma with giant cells, infiltrating bladder urothelial carcinoma with glandular differentiation, infiltrating bladder urothelial carcinoma with trophoblastic differentiation, infiltrating bladder urothelial carcinoma, clear cell variant, infiltrating bladder urothelial carcinoma, micropapillary variant, infiltrating bladder urothelial carcinoma, nested variant, infiltrating bladder urothelial carcinoma, plasmacytoid variant